Ordering Recommendation

Carrier screening or diagnostic testing for maple syrup urine disease type 1B for individuals of Ashkenazi Jewish descent.

Mnemonic
BCKDHB
Methodology

Polymerase Chain Reaction/Fluorescence Monitoring

Performed

Tue, Fri

Reported

5-10 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Specimens collected in sodium heparin or lithium heparin tubes.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 month

Reference Interval

By report

Interpretive Data

Background Information for Maple Syrup Urine Disease, Type 1B (BCKDHB), 3 Variants:
Characteristics: Maple syrup urine disease (MSUD), type 1B most commonly presents in the first few days of life. Symptoms include irritability, poor feeding, lethargy, intermittent apnea and typically progresses to coma and death within 7 to 10 days if untreated.
Incidence: 1 in 50,000 in Ashkenazi Jewish individuals.
Inheritance: Autosomal recessive.
Cause: BCKDHB pathogenic variants.
Variants Tested: p.R183P (c.548G>C), p.G278S (c.832G>A), p.E372X (c.1114G>T).
Clinical Sensitivity: 99 percent in Ashkenazi Jewish individuals; unknown in other ethnicities.
Methodology: Polymerase chain reaction (PCR) and fluorescence monitoring.
Analytical Sensitivity and Specificity: Greater than 99 percent.
Limitations: Variants other than those tested will not be detected. Diagnostic errors can occur due to rare sequence variations.

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
Hotline History
N/A
CPT Codes

81205

Components
Component Test Code* Component Chart Name LOINC
2013731 Maple Syrup Urine Disease, Specimen
2013732 Maple Syrup Urine Disease, Allele 1
2013733 Maple Syrup Urine Disease, Allele 2
2013734 Maple Syrup Urine Disease, Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • MSUD
Maple Syrup Urine Disease, Type 1B (BCKDHB), 3 Variants